Ensysce Biosciences, Inc.
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company developing abuse-deterrent opioid formulations, specifically PF614 and PF614-MPAR, relying on third-party contract research organizations for development and generating minimal revenue from licensing or collaboration agreements.
Business. Ensysce Biosciences, Inc. (ENSC) is a pharmaceutical company headquartered in the United States that operates within the Healthcare sector. The firm is primarily engaged in the development and commercialization of pharmaceutical products, with its common stock listed on the Nasdaq stock exchange. As specific operating segment and geographic revenue data are not provided, the company is described at the industry level as a participant in the broader pharmaceuticals market.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Ensysce Biosciences, Inc. (ENSC) has recorded a notable addition to its shareholder base, marking the first material change identified for the ticker. As of June 30, 2024, a new investor (ID 466) acquired 975 shares, representing a portfolio weight of approximately 1.12e-08 percent and a value of $0.000494 million [ensc-companyfacts]. This activity was detected on June 28, 2026, signaling renewed or initial institutional interest in the company’s equity structure. This shareholder addition is significant given Ensysce’s current corporate profile, which includes a single officer and no analyst coverage [ensc-companyfacts]. With zero analysts currently tracking the stock and no index memberships, the company operates with limited public market visibility. The entry of a new holder, even with a minimal weight, stands out against a backdrop of sparse professional scrutiny and a small top holder count of four. The lack of prior basis for delta computation in this first analysis underscores the novelty of this data point for ENSC [ensc-companyfacts]. Without historical comparative metrics or cross-source signals to contextualize the move, the significance of the share acquisition rests primarily on the fact of the addition itself. It suggests that despite the absence of analyst estimates or broader market indices, specific investors are monitoring or entering positions in the biosciences firm. For investors, this development highlights the importance of monitoring holder changes in low-coverage stocks. Ensysce’s structure, characterized by minimal officer count and no analyst presence, means that individual holder actions may carry disproportionate informational weight. The addition of investor ID 466 serves as an early indicator of potential interest, warranting attention as the company continues to report through its recent 10-Q and 10-K filings [ensc-10-q-2026-05-15, ensc-10-k-2026-03-30].
Signals & dispatch
Composite-score breakdown
Synthesis
Ensysce Biosciences, Inc. (ENSC) is a pharmaceutical company headquartered in the United States that operates within the Healthcare sector. The firm is primarily engaged in the development and commercialization of pharmaceutical products, with its common stock listed on the Nasdaq stock exchange. As specific operating segment and geographic revenue data are not provided, the company is described at the industry level as a participant in the broader pharmaceuticals market.
Ensysce Biosciences operates with a negative equity position of -$340,042 and total liabilities of $2,836,815 exceeding total assets of $2,167,803 as of Q1 2026. The current ratio stands at 0.71, indicating that current liabilities exceed current assets, while cash and equivalents total $745,482. Operating cash flow for the period was -$3,500,925, reflecting significant cash burn. The debt-to-equity ratio is reported as -0.0 due to the negative equity base, and the market capitalization is $1,992,996 at a share price of $0.2914.
Profitability remains deeply negative, with an operating income of -$3,562,230 against revenue of $960,999 in Q1 2026. The company reports an EV/EBITDA of -0.35 and an EV/Revenue of 1.3. Analyst estimates project a mean EPS of -$1.53 and mean revenue of $7,300,000, contrasting with the last actual EPS of -$3.98 and revenue of $5,066,650. The company lacks positive returns on equity or assets, consistent with its pre-commercial development stage.
Ensysce Biosciences, Inc. (ENSC) has recorded a notable addition to its shareholder base, marking the first material change identified for the ticker. As of June 30, 2024, a new investor (ID 466) acquired 975 shares, representing a portfolio weight of approximately 1.12e-08 percent and a value of $0.000494 million [ensc-companyfacts]. This activity was detected on June 28, 2026, signaling renewed or initial institutional interest in the company’s equity structure. This shareholder addition is significant given Ensysce’s current corporate profile, which includes a single officer and no analyst coverage [ensc-companyfacts]. With zero analysts currently tracking the stock and no index memberships, the company operates with limited public market visibility. The entry of a new holder, even with a minimal weight, stands out against a backdrop of sparse professional scrutiny and a small top holder count of four. The lack of prior basis for delta computation in this first analysis underscores the novelty of this data point for ENSC [ensc-companyfacts]. Without historical comparative metrics or cross-source signals to contextualize the move, the significance of the share acquisition rests primarily on the fact of the addition itself. It suggests that despite the absence of analyst estimates or broader market indices, specific investors are monitoring or entering positions in the biosciences firm. For investors, this development highlights the importance of monitoring holder changes in low-coverage stocks. Ensysce’s structure, characterized by minimal officer count and no analyst presence, means that individual holder actions may carry disproportionate informational weight. The addition of investor ID 466 serves as an early indicator of potential interest, warranting attention as the company continues to report through its recent 10-Q and 10-K filings [ensc-10-q-2026-05-15, ensc-10-k-2026-03-30].
- Negative equity of -$340,042 and a current ratio of 0.71 signal severe liquidity constraints and high risk of insolvency without additional capital.
- Operating cash flow of -$3,500,925 in Q1 2026 underscores a high burn rate, necessitating frequent dilutive financing events.
- Filings explicitly reference going-concern doubts and substantial-doubt language, elevating the risk profile for investors.
- Analyst price targets of $16.45 imply a significant re-rating potential, but this is contingent on successful clinical outcomes for PF614 and PF614-MPAR.
- Recent warrant inducements and registered direct offerings indicate ongoing pressure to raise capital, contributing to medium dilution risk.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue $961.0k; Operating income -$3.6M.
- ▍Revenue $961.0k
- ▍Operating income -$3.6M
- ▍Operating margin -370.7%
Revenue $3.2M; Operating income -$7.5M.
- ▍Revenue $3.2M
- ▍Operating income -$7.5M
- ▍Operating margin -234.2%
Revenue $2.7M; Operating income -$3.7M.
- ▍Revenue $2.7M
- ▍Operating income -$3.7M
- ▍Operating margin -138.2%
Revenue $5.1M; Operating income -$10.2M.
- ▍Revenue $5.1M
- ▍Operating income -$10.2M
- ▍Operating margin -202.1%
Revenue $5.2M; Operating income -$6.7M.
- ▍Revenue $5.2M
- ▍Operating income -$6.7M
- ▍Operating margin -129.2%
Revenue $5.2M; Operating income -$6.7M.
- ▍Revenue $5.2M
- ▍Operating income -$6.7M
- ▍Operating margin -129.2%
Revenue $2.2M; Operating income -$10.7M.
- ▍Revenue $2.2M
- ▍Operating income -$10.7M
- ▍Operating margin -480.5%
Revenue $2.2M; Operating income -$10.7M.
- ▍Revenue $2.2M
- ▍Operating income -$10.7M
- ▍Operating margin -480.5%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -1,53 |
| Revenue | —no estimate | —no estimate | 7,3M USD |
| Operating income | —no estimate | —no estimate | —no estimate |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Current liabilities exceed current assets.
- Filings reference going-concern or substantial-doubt language.
- Source documents mention dilution or offering risk.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Regulatory filings
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
- Ev To Revenueenterprise_value / revenue
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Enterprise Valuemarket_cap - net_cash
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Ensysce Biosciences, Inc. company facts · 2026-07-16
- Ensysce Biosciences, Inc. 10-Q 2026-05-15 · 2026-07-16
- Ensysce Biosciences, Inc. 10-K 2026-03-30 · 2026-07-16
- Ensysce Biosciences, Inc. 10-Q 2025-11-14 · 2026-07-16
- Ensysce Biosciences, Inc. 10-Q 2025-08-13 · 2026-07-16
- 8-K (sec_8k_material) on ENSC · 2026-07-16
- Ensysce Biosciences Inc Market data — analyst estimates · 2026-07-16
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$0M
Leadership
- Lynn D. KirkpatrickPresident, Chief Executive Officer, Director
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Shares outstanding (annual): 4.57MUnknown
- Capex (annual): USD 123.64KUnknown
- Operating cash flow (annual): USD -7.81MUnknown
- EPS (basic) (annual): USD-PER-SHARES -4Unknown
- EPS (diluted) (annual): USD-PER-SHARES -4Unknown
- Current liabilities (annual): USD 4.57MUnknown
- Cash & equivalents (annual): USD 4.31MUnknown
- Total liabilities (annual): USD 4.57MUnknown
- Shareholders' equity (annual): USD 3.21MUnknown
- R&D expense (annual): USD 10.38MUnknown
- Current assets (annual): USD 7.25MUnknown
- Total assets (annual): USD 7.45MUnknown
- Operating income (annual): USD -10.24MUnknown
- Total operating expenses (annual): USD 15.31MUnknown
- Revenue (annual): USD 5.07MUnknown
- Operating income (annual): USD -6.73MUnknown
- Revenue (annual): USD 5.21MUnknown
- Shares outstanding (annual): 1.36MUnknown
- Current liabilities (annual): USD 2.21MUnknown
- Operating cash flow (annual): USD -7.5MUnknown
- Shareholders' equity (annual): USD 3.71MUnknown
- Total liabilities (annual): USD 2.22MUnknown
- Current assets (annual): USD 5.34MUnknown
- Total operating expenses (annual): USD 11.94MUnknown